Dolutegravir (Tivicay) for the indication infection with HIV-1

The WAR has approved a pharmacotherapeutic report for the medicine dolutegravir (Tivicay). In determining its therapeutic value, dolutegravir was compared with the standard treatments or usual treatments for HIV-1 infection in adults.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.